Incyte wins first US OK for JAK inhibitor with myelofibrosis drug Jakafi
This article was originally published in Scrip
Executive Summary
Continuing on its trend this year to give its blessing to oncology products before their expected action date, the US FDA on 16 November granted the OK to Incyte's myelofibrosis (MF) drug Jakafi (ruxolitinib) – the first and only prescription medicine approved in the US for that indication (scripintelligence, 4 November 2011).